Introduction {#Sec1}
============

More than 20 years have passed since stents began to be used for treating unresectable bile duct stricture in patients with obstructive jaundice. Previously, percutaneous transhepatic cholangial drainage (PTCD); also known as percutaneous transhepatic biliary drainage (PTBD) was employed for patients with this disease, and the patients were often forced to stay in hospital for a long period of time with an external biliary fistula. The creation of an internal fistula is now widely used because it is as useful as surgical bypass in improving not only quality of life (QOL) but also survival rates. Today, noninvasive endoscopic stent placement is being used for most patients with this disease as an alternative procedure to the percutaneous approach. Plastic stents (PS), which have been used until now, are economical, but their shortcoming is that they give rise to obstruction at an earlier stage, so several improvements have been made. On the other hand, metal stents (MS), in which the insertion of the stents is enabled with a slender delivery system and the stents expand to a large diameter by themselves, have conferred noticeably extended patency compared with PS. However, their shortcomings are that they are more expensive than PS and replacing them is difficult once they have been placed.

Here we pose clinical questions (CQs) regarding stenting for obstructive jaundice in patients with unresectable biliary carcinoma, with responses in the form of recommendations (grades of the recommendations are defined in Table [1](#Tab1){ref-type="table"}[@CR1]). Also, levels of evidence are given (in parentheses) for findings in reference citations (see definitions of levels in Table [2](#Tab2){ref-type="table"}[@CR1]). Table 1Strength of recommendations[@CR1]A, Strongly recommend performing the clinical actionB, Recommend performing the clinical actionC1, The clinical action may be considered although there is a lack of high-level scientific evidence for its use. May be usefulC2, Clinical action not definitively recommended because of insufficient scientifi cevidence. Evidence insuffi cient to support or deny usefulnessD, Recommend not performing the clinical actionTable 2Levels of evidence[@CR1]Level ISystematic review/meta-analysisLevel IIOne or more randomized clinical trialsLevel IIINonrandomized controlled trialsLevel IVAnalytic epidemiology (cohort studies and case-control studies)Level VDescriptive study (case reports and case-series studies)Level VIOpinions of expert panels and individual experts not based on patient's data

CQ 1 Is biliary drainage recommended for patients with unresectable disease? {#Sec2}
============================================================================

Biliary drainage should be performed (recommendation B).

There are many studies reporting the approach route of drainage for unresectable malignant distal biliary obstruction, methods of stenting, and the quality of stent materials. In view of this situation, it is thought that the relief of jaundice should be conducted as a matter of course. Also, the creation of an internal fistula, where possible, is recommended.

For the drainage route, there are reports of randomized controlled trials (RCTs)[@CR2],[@CR3] (level II) comparing endoscopic drainage, PTBD, and surgical drainage. The success rate for the creation of an internal fistula is reported to be 95%--100%[@CR4],[@CR5] (levels II, IV). According to these reports, endoscopic drainage is preferable to the other two methods. A metaanalysis showed that endoscopic drainage was associated with a lower risk of complications, but a higher risk of recurrent biliary obstruction than surgical drainage[@CR4] (level II). The percutaneous procedure is performed in patients in whom the endoscopic procedure has been unsuccessful.

Concerning the types of stent available, there are several RCTs suggesting the superiority of metal stents over plastic stents with respect to stent patency[@CR4]--[@CR12] (level II).

For hepatic hilar bile duct stricture, placement of multiple stents has been reported to confer better drainage effects than those brought about by single-stent placement[@CR13] (level IV), although there are also prospective trials demonstrating that single stents are as effective as multiple stents[@CR14],[@CR15] (levels II, III). However, there are several questions as to hepatic hilar bile duct stricture, such as the presence of segments for which drainage is unable to be achieved and the clogging of stents, so stent placement in these patients is still controversial.

CQ 2 Which type of biliary stent is appropriate for unresectable cases? {#Sec3}
=======================================================================

Ametal stent is preferable in view of stent patency (recommendation C1).

Plastic stents with an outer diameter of 8--10 Fr are now in use (Fig. [1](#Fig1){ref-type="fig"}). These are easily clogged, so stents with a larger diameter have occasionally been employed in the past. However, due to the pain and technical difficulties accompanying the insertion of these stents, they have fallen into disuse. Improvements have been made in the quality of materials and the shape of stents, but no difference in patency rates has been observed[@CR16]--[@CR19] (level II). Fig. 1Plastic stents. From *left*, plastic stents with outer diameters of 10, 8.5, and 7 Fr, are shown

There are RCTs comparing plastic stents with metal stents in the palliative treatment of distal malignant biliary obstruction[@CR4]--[@CR11] (level II). As for the median patency of stents, metal stents (3.6--9.1 months) are significantly superior to plastic stents (1.8--5.5 months), but no difference was found in median survival (Table [3](#Tab3){ref-type="table"}).[@CR20] Although metal stents are expensive, their overall cost, including hospitalization expenses, is thought to be lower compared with that of plastic stents because of the reduced frequency of re-intervention.[@CR7],[@CR7] According to recent reports, the cost of plastic stents is low for the reasons that, in patients for whom prognosis is poor, long-term survival is not expected (patients with liver metastasis) and re-intervention is also unnecessary.[@CR8]--[@CR10] In patients for whom long-term survival exceeding 6 months is expected, metal stents may be used from the initial intervention, while in patients for whom survival exceeding 6 months is not expected, similar results are achieved by using plastic stents (level IV). Table 3Prospective and randomized controlled trials for plastic versus metal stents in the palliative treatment of distal malignant biliary obstruction[@CR6]--[@CR11],[@CR20]ReferenceStent groupNo. of patientsStent occlusion*P*Stent patency (months)*P*Median survival (months)*P*Davids et al.,[@CR6] 1992MS4916NR9.10.0065.80.45PS56304.24.9Knyrim et al.,[@CR7] 1993MS316NR6.2NRNRNRPS31104.6NRPrat et al.,[@CR8] 1998MS34NRNR4.8\<0.05^e^4.5NSPS^a^34NR3.25.6PS^b^33NR3.24.8Kaassis et al.,[@CR9] 2003MS5911\<0.007NR0.0075.1NSPS59225.53.3Katsinelos et al.,[@CR10] 2006MS2323NS8.50.0029.1NSPS^c^24244.16.9Soderlund et al.,[@CR11] 2006MS^d^4990.0093.60.0025.30.27PS51221.83.976MS, metal stent; PS, plastic stent; NR, not reported; NS, not signifi cant^a^ Stent exchanged every 3 months with or without evidence of stent dysfunction^b^ Stent exchanged on evidence of stent dysfunction^c^ Tannenbaum stent^d^ Covered MS^e^ MS versus PSa and PS^b^

In metal stents, which are made of mesh materials, obstruction due to the ingrowth of tumors has often occurred. To cope with this problem, polyurethane-covered metal stents have become available in clinical settings (Fig. [2](#Fig2){ref-type="fig"})[@CR21] (level IV), and their superior patency has been demonstrated by an RCT[@CR22] (level II). Recent case series studies, however, reported that no significant difference in patency rate was found between covered and uncovered metal stents, because covered metal stents have several drawbacks, such as stent-migration and the occurrence of acute cholecystitis[@CR23]--[@CR25] (level IV). Furthermore patients with pancreatic cancer have been included in the results of studies of stent treatment for malignant distal biliary stricture. Accumulation of evidence is awaited. Fig. 2Covered metal stent (Wallstent; Boston Scientific, Natick, MA, USA). This metal stent is partially covered

There is much controversy as to the importance of establishing drainage of both liver lobes in malignant hilar biliary obstruction. Drainage with a unilateral uncovered metal stent is reported to be effective for hilar biliary obstruction[@CR15],[@CR26],[@CR27] (level III, IV); however, there are no RCTs regarding unilateral or bilateral metal stent drainage. Concerning plastic stents, an RCT failed to find any difference in drainage effects between single stents and multiple stents[@CR15] (level II). Although an RCT[@CR12] (level II) regarding plastic stents and metal stents showed that both success and patency rates were better for metal stents than for plastic stents, the RCT included only 20 patients with hilar biliary obstruction. Hence, it is still controversial which type of stents should be used in patients with hilar biliary obstruction.
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